OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kamdar on the Results of the TRANSFORM Trial in Relapsed/Refractory LBCL

December 11th 2021

Manali Kamdar, MD, discusses the results of the phase 3 TRANSFORM trial in relapsed/refractory large B-cell lymphoma (LBCL) that were presented during the 2021 ASH Annual Meeting & Exposition.

Dr. McKinney on Emerging Therapeutic Strategies in MCL

December 10th 2021

Matthew S. McKinney, MD, cellular therapy specialist, hematologic oncologist, hematologist (malignant), Duke Health, discusses emerging therapeutic strategies in mantle cell lymphoma (MCL).

Dr. Randall on the Evolution of Limb Salvage Technologies in Bone Sarcomas

December 10th 2021

R. Lor Randall, MD, FACS, discusses the evolution of limb salvage technologies in bone sarcomas.

Dr. Bardia on the Efficacy Results of the EMERALD Trial in ER+/HER2- Breast Cancer

December 10th 2021

Aditya Bardia, MD, MPH, discusses the efficacy results of the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative metastatic breast cancer.

Dr. Ganz on the Quality of Life Results From the OlympiA Trial in BRCA-Mutated Breast Cancer

December 10th 2021

Patricia A. Ganz, MD, discusses the quality of life results from the phase 3 OlympiA trial in BRCA-mutated breast cancer.

Dr. Kruse on the Results of a Study Comparing Outcomes in Pleomorphic Vs Non-Pleomorphic Invasive Lobular Carcinoma

December 10th 2021

Megan Kruse, MD, discusses the results of a study comparing clinical features and outcomes of pleomorphic vs non-pleomorphic invasive lobular carcinoma.

Dr. Heyman on ROR1-Targeted Approaches in Relapsed/Refractory MCL

December 9th 2021

Benjamin Heyman, MD, discusses agents targeting ROR1 in patients with relapsed/refractory mantle cell lymphoma.

Dr. Schmid on Additional Results From the KEYNOTE-522 Trial in Early-Stage TNBC

December 9th 2021

Peter Schmid, MD, PhD, FRCP, discusses additional results from the phase 3 KEYNOTE-522 trial in early-stage triple-negative breast cancer.

Dr. Hurvitz on the Results of Subgroup Analyses From DESTINY-Breast03 in HER2+ Breast Cancer

December 9th 2021

Sara A. Hurvitz, MD, discusses the results of subgroup analyses from the phase 3 DESTINY-Breast03 trial in patients with HER2-positive metastatic breast cancer.

Dr. Azzi on the Utility of Signatera as a Preferred ctDNA Assay in CRC

December 8th 2021

Georges Azzi, MD, discusses the utility of the Signatera circulating tumor DNA assay as a preferred test in colorectal cancer (CRC).

Dr. Lipson on the Role of ctDNA Testing in Melanoma

December 8th 2021

Evan J. Lipson, MD, discusses the role of circulating tumor DNA testing in melanoma.

Dr. Spitalnik on Goals for the Hemanext® Blood Storage System in Hematologic Malignancies

December 8th 2021

Steven L. Spitalnik, MD, discusses the goals for the Hemanext® blood storage system in patients with hematologic malignancies.

Dr. Arnaoutakis on the ADAURA Trial Examining Osimertinib in EGFR-Mutant Lung Cancer

December 8th 2021

Konstantinos Arnaoutakis, MD, discusses the phase 3 ADAURA trial examining osimertinib in the adjuvant treatment of patients with EGFR-mutant lung cancer.

Dr. Anders on Leveraging ADCs in Metastatic TNBC

December 8th 2021

Carey K. Anders, MD, discusses leveraging antibody-drug conjugates in the treatment of patients with metastatic triple-negative breast cancer.

Dr. Kalinsky on Updated Results From the RxPONDER Trial in HR+/HER2- Breast Cancer

December 8th 2021

Kevin Kalinsky, MD, MS, discusses updated results from the phase 3 RxPONDER trial in patients with hormone receptor-positive, HER2-negative breast cancer.

Dr. Fernandez on the Results of a Study Examining Low HER2 Expression in Breast Cancer

December 8th 2021

Aileen I. Fernandez, PhD, discusses the results of a study examining low HER2 expression in breast cancer.

Dr. Vaishampayan on the Utility of FGFR Inhibitors in Urothelial Cancer

December 8th 2021

Ulka Nitin Vaishampayan, MBBS, discusses the utility of FGFR inhibitors in metastatic urothelial cancer.

Dr. Shore on the Rationale for the Phase 2 ENACT Trial in Prostate Cancer

December 8th 2021

Neal D. Shore, MD, FACS, discusses the rationale for the open-label, randomized phase 2 ENACT trial in prostate cancer.

Dr. Lonial on the Management of Belantamab Mafodotin–Related Keratopathy in Multiple Myeloma

December 8th 2021

Sagar Lonial, MD, FACP, discusses the management of belantamab mafodotin-blmf–related keratopathy in patients with relapsed/refractory multiple myeloma.

Dr. Raghav on Treatment Considerations in Metastatic CRC

December 8th 2021

Kanwal Raghav, MBBS, MD, discusses treatment considerations in metastatic colorectal cancer.